In vivo synergistic anti-tumor effect of paclitaxel nanoparticles combined with radiotherapy on human cervical carcinoma

Figures & data

Figure 1. Physicochemical characterization and stability study of PTX-NPs. (A) PTX-NPs particle size distribution; (B) TEM image of PTX-NPs and (C) the formulation stability of the PTX-NPs. Data are shown as means ± SD (n = 3).

Table 1. PTX content in nanoparticles.

Samples	Theoretical DL (%)	DL (%)	EE (%)	Size (nm)	PDI
1	6%	4.33 ± 0.12	92.76 ± 0.29	43.34 ± 0.27	0.21 ± 0.04
2	8%	7.96 ± 0.06	99.78 ± 0.34	45.71 ± 0.32	0.19 ± 0.02
3	10%	9.79 ± 0.17	97.90 ± 0.17	49.36 ± 0.40	0.20 ± 0.05

Figure 2. In vitro drug release of PTX-NPs and free PTX. Data are shown as means ± SD (n = 3).

Figure 3. PTX-NPs + RT inhibited tumor growth in subcutaneous HeLa model. (A) Suppression of subcutaneous tumor growth in each group. (B) Mice survival curve in each group.

Figure 4. Representative 18F-FDG PET images of mice after one full day treatment.

Figure 5. Ki-67 immunohistochemical staining in tumors. (A) Ki-67 immunohistochemical images of tumor tissue from mice in various groups. (B) Ki-67 quantitative analysis in xenografts from mice in various groups. *p < 0.05 and **p < 0.01. Original magnification, ×400.

Figure 6. CD31 immunohistochemical staining of tumors. (A) CD31 immunohistochemical images of tumor tissue from mice in various groups. (B) CD31 quantitative analysis in xenografts from mice in various groups. *p < 0.05 and **p < 0.01. Original magnification, ×400.

Figure 7. VEGF immunohistochemical staining in tumors. (A) VEGF immunohistochemical images of tumor tissue from mice in various groups. (B) VEGF quantitative analysis in xenografts from mice in various groups. *p < 0.05 and **p < 0.01. Original magnification, ×400.